ライフサイエンスコーパス: oxymorphone

1 d its two main metabolites, noroxycodone and oxymorphone.

2 xycodone in the presence of noroxycodone and oxymorphone.

3 th other strong opioids, such as morphine or oxymorphone.

4 in the past years, including hydrocodone and oxymorphone.

5 essentially equipotent with one another and oxymorphone.

6 ds, naltrindole (1, NTI) and 7-(spiroindanyl)oxymorphone (2, SIOM), at delta opioid receptors.

7 Ls: 12,13-diHOME, 9,10-diHOME, lysoPC(15:0), oxymorphone-3b-D-glucuronide, cortisone, and oleoyl-glyc

8 Oxymorphone 80 mg/day had the highest risk of dropouts d

9 nsubstituted pyridomorphinans possessing the oxymorphone and hydromorphone framework displayed nearly

10 e variants of the mu opioid receptor agonist oxymorphone and the antagonist naloxone.

11 lease formulation of the prescription opioid oxymorphone, and 92.3% were coinfected with hepatitis C

12 uding hydrocodone, oxycodone, hydromorphone, oxymorphone, and codeine.

13 robenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone (4-9).

14 s of pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone (7a-k) were synthesized a

15 Methylnaltrexone, hydromorphone, oxymorphone, and meptazinol were identified as OCT1 subs

16 ingredients in reformulated extended-release oxymorphone can elicit TMA.

17 ization and internalization; 2) morphine and oxymorphone caused significant desensitization without e

18 n smooth muscle assays has revealed that the oxymorphone derivatives (6, 7) are delta-selective agoni

19 cophores derived from NTI and the mu agonist oxymorphone, have been synthesized and evaluated by intr

20 (TMA) following IV abuse of extended-release oxymorphone hydrochloride (Opana ER), an oral opioid for

21 Local photo-uncaging of oxymorphone in the DRN produced conditioned place prefer

22 ting concentrations of etorphine, methadone, oxymorphone, or beta-CNA also reduced the current induce

23 sing MAI for a mixture of morphine, codeine, oxymorphone, oxycodone, clozapine, and buspirone and the

24 ptors in vivo, we developed photoactivatable oxymorphone (PhOX) and photoactivatable naloxone (PhNX),

25 nt injection of adulterated extended-release oxymorphone tablets.

26 own immunosuppressive properties (oxycodone, oxymorphone, tramadol) accounting for demographics, opio

27 inaphthyl (11) derivatives of naltrexone and oxymorphone were synthesized in order to investigate the

28 action of the benzylimines of oxycodones and oxymorphones with nitrostyrenes gave a series of 4'-aryl

29 Injection-drug use of extended-release oxymorphone within a network of persons who inject drugs